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Abstract
Background: In worldwide, the mortality rate of acute myocardial infarction (AMI) raises year by year. Although the
applications of percutaneous coronary intervention (PCI) and anticoagulants effectively reduce the mortality of patients
with acute coronary syndrome (ACS), but also increase the incidence of bleeding. Therefore, drugs with stable
anticoagulant effects are urgently required.
Methods: We enrolled 894 patients with acute coronary syndrome who underwent percutaneous coronary intervention
in Shenyang Northern Hospital from February 2010 to May 2012; 430 patients were included in the fondaparinux group
(2.5 mg/d), and 464 were included in the enoxaparin group (1 mg/kg twice daily). Fondaparinux and enoxaparin were
applied for 3–7 days. All patients were treated with tirofiban (10 μg/kg for 3 min initially and 0.15 μg/(kg · min) for 1 to
3 days thereafter). The primary efficacy endpoint was the incidence of a major adverse cerebrovascular or cardiovascular
event. The primary safety endpoint was bleeding within 30 days and 1 year after percutaneous coronary intervention.
Results: One-year data were available for 422 patients in the fondaparinux group and for 453 in the enoxaparin group.
The incidence of a major adverse cerebrovascular or cardiovascular event (10.9 % vs 12.6 %, P = 0.433) and cardiac
mortality (0.5 % vs 1.5 %, P = 0.116) were generally lower in the fondaparinux group than in the enoxaparin group,
although the differences were not significant. Compared with the enoxaparin group, the fondaparinux group had a
significantly decreased rate of bleeding at 30 days (0.9 % vs 2.8 %) and 1 year (2.4 % vs 5.4 %). In addition, the rate of
major bleeding events was lower in the fondaparinux group, but this difference was not significant (0.2 % vs 0.9 %,
0.2 % vs 1.1 %).
Conclusions: In tirofiban-treated patients with acute coronary syndrome undergoing percutaneous coronary
intervention, fondaparinux presented similar efficacy for ischemia events as enoxaparin. However, fondaparinux
significantly decreased the incidence of bleeding, thus providing safer anticoagulation therapy.
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Background
Approximately 55 million people die each year world-
wide. An epidemiological survey reports that approxi-
mately 30 % die from cardiovascular diseases, and
almost 40–50 % of these deaths are caused by acute
myocardial infarction (AMI) [1]. Therefore, timely and
effective treatments for acute coronary syndrome
(ACS) play an important role in reducing the mortality
of patients with ACS. ACS is mainly due to the erosion
of the fibrous cap on the coronary artery atheromatous
surface. After this erosion, platelets adhere and aggre-
gate to the ruptured surface. Ultimately, thrombosis oc-
curs due to activation of the blood coagulation cascade.
According to the degree of arterial obstruction, ACS is di-
vided into unstable angina, ST segment elevation myocar-
dial infarction (STEMI), and non-ST segment elevation
myocardial infarction (NSTEMI).
As anticoagulants, unfractionated heparin (UFH) and
low-molecular-weight heparin (LMWH) have success-
fully been used to reduce the incidence of ischemic
complications in patients with ACS undergoing percu-
taneous coronary intervention (PCI); however, these
agents also increase the incidence of bleeding [2, 3].
Patients with ACS have serious coronary insufficiency,
and the anticoagulant activity is unpredictable. Therefore,
drugs with stable anticoagulant effects are urgently re-
quired. Platelet activation and aggregation play crucial
roles in the blood coagulation cascade, which causes MI
events and thrombotic complications in the perioperative
period of PCI. Previously obtained data have shown that
the inhibition of platelet activity that results from the ap-
plication of glycoprotein IIb/IIIa inhibitors (GPIs) during
PCI is effective for protection against ischemic events [4].
GPIs act by inhibiting fibrinogen and von Willebrand
factor, which mediate platelet cross-linkage, the final stage
of platelet aggregation. In Europe and the United States,
GPIs are frequently used in patients with STEMI who are
undergoing PCI to reduce the incidence of ischemic com-
plications [5–7]. However, the application of antiplatelet
therapy and thrombolytic therapy during PCI can ap-
parently increase the incidence of hemorrhagic events
and thrombocytopenia [8–11], and major bleeding can
predict myocardial infarction, stroke and death [12].
Consequently, although antiplatelet and thrombolytic
therapies for ACS have the benefit of restoring perfusion
by preventing further platelet aggregation and thrombotic
formation, they also reduce the risk of ischemic events;
however, this comes at the cost of a higher risk of
bleeding. Therefore, clinical studies are attempting to
determine how to maximize the benefit while minimizing
the risk associated with anticoagulant therapy.
The synthetic inhibitor of coagulation factor X, fonda-
parinux, (Arixtra; GlaxoSmithKline) has been recently
evaluated in patients with ACS who were enrolled in the
Fifth and Sixth Organization to Assess Strategies in Is-
chemic Syndromes (OASIS 5 and 6) trials [13, 14]. In
these trials, patients were treated using conservative or
invasive strategies. The OASIS-5 trial demonstrated that
in >20,000 patients with NSTEMI, fondaparinux reduced
major bleeding by 50 % and reduced mortality by 17 %
at 9 days compared with enoxaparin [13]. The anti-
coagulant enoxaparin is superior to UFH in reducing the
risk of MI or death [15]. Although the beneficial effects
of fondaparinux at 9 and 30 days are known, the results
at 1 year remain unknown. The objective of the present
study was to detect the efficacy and safety of fondapari-
nux and enoxaparin in patients with ACS undergoing
PCI when treated with GPI tirofiban.
Methods
Participants
In this study, we collected information regarding patients
with ACS who underwent PCI in Shenyang Northern
Hospital from February 2010 to May 2012; all patients
were treated with tirofiban, and 894 patients were en-
rolled. Of these, 430 patients were enrolled in the fonda-
parinux (2.5 mg/d) group, and 464 were enrolled in the
enoxaparin group (1 mg/kg twice daily) for the index pro-
cedure. Fondaparinux and enoxaparin were administered
for 3–7 days according to the coronary artery lesions
during PCI. All patients were treated with tirofiban
(10 μg/kg for 3 min initially and 0.15 μg/(kg · min) for 1
to 3 days thereafter). All patients and their relatives pro-
vided informed consent, and the study was approved by
the ethical committee of Shenyang Northern Hospital.
Patients aged ≥18 years were eligible for enrollment if
they exhibited ischemic symptoms within 24 h and met
the following criteria: (1) elevated creatine kinase–myo-
cardial band (CK-MB) isoenzyme or troponin, or an elec-
trocardiographic change indicating ischemia; (2) planned
elective PCI; (3) treated with GPI tirofiban. The patients
were also treated with enteric-coated aspirin, clopidogrel,
nitrates, β-blockers, angiotensin-converting enzyme inhib-
itors (ACEI) or angiotensin receptor blockers (ARBs) and
statins.
The following exclusion criteria were applied: planned
to undergo emergency PCI in patients with ACS; treated
with thrombolysis within 3 days of STEMI; left main
coronary artery disease; cardiogenic shock with a high pos-
sibility of vascular lesions or secondary bleeding, such as
gastric ulcer or intracranial aneurysm; planned to undergo
coronary artery bypass surgery; previous treatment with
fibrinolytic therapy, such as bivalirudin, GPI, LMWH, or
fondaparinux (UFH was allowed); current application of
Coumadin; stroke or transient ischemic attack within the
past 6 months; digestive tract or urinary tract hemorrhage
within the past 3 months; cerebral infarction within the
past 3 months and cerebral hemorrhage within the past
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6 months; platelet count <100,000 cells/μl or hemoglobin
concentration <100 g/L; planned elective surgical proced-
ure that would necessitate anticoagulation interruption;
coronary stent implantation within the past 30 days; abnor-
mal liver function (alanine aminotransferase or aspartate
aminotransferase 1.5 times normal value) or renal impair-
ment (serum creatinine level >180 mmol/L).
Outcome
The primary efficacy endpoint was the occurrence of
major adverse cerebrovascular or cardiovascular events
(MACCEs), which were defined as comprising cardiac
mortality, non-fatal MI, emergent target vessel revascu-
larization (TVR), and ischemic stroke at 1 year. The pri-
mary safety endpoints were bleeding events within
30 days and 1 year after index PCI and were evaluated
using the thrombolysis in myocardial infarction (TIMI)
definition. MI was defined as follows: prolonged ische-
mic symptoms with CK-MB isoenzyme levels more than
three times the upper limit of normal, electrocardio-
graphic changes indicating ischemia or the appearance
of new Q waves. TVR included intervention due to the
recurrence of any part of the original vessel. Bleeding
events were as defined by the TIMI test group and were
divided into major, secondary and minor bleeding [16].
Statistical analysis
The data were analyzed using SPSS version 19.0. Base-
line characteristics were represented as means ± SD or
medians (range) and were compared using the t test;
proportions were compared using the χ2 test. Fisher’s
test was used to compare exact probability. A Cox pro-
portional hazards model was used to analyze MACCEs
and all bleeding events in the fondaparinux and enoxa-
parin groups. The Cox proportional hazards model was
used to calculate the odds ratios for the morbidity of
MACCEs in the two groups. All P values were two-
tailed, and statistical significance was defined as P < 0.05.
Results
As described above, there were 430 patients in the fon-
daparinux group and 464 in the enoxaparin group at en-
rollment. Follow-up data were available for 422 (98.1 %)
patients in the fondaparinux group and 453 (97.8 %) in
the enoxaparin group. Reasons for dropout were loss to
follow-up or withdrawal of consent (Fig. 1).
The baseline clinical characteristics of sex, age, weight,
operative condition for PCI, and application of tirofi-
ban did not significantly differ between the two groups
(P > 0.05); in addition, the application period of fondapari-
nux and enoxaparin did not significantly differ between
the two groups (4.75 ± 1.81 vs 4.57 ± 1.75, P = 0.168).
However, the proportion of patients with STEMI was
higher in the fondaparinux group than that in the enox-
aparin group (37.7 % vs 25.6 %, P < 0.001, Table 1). Ad-
ministration of enteric-coated aspirin, clopidogrel, ACE
inhibitors, ARBs, calcium channel blockers, β-blockers,
and statins during the follow-up period did not differ
significantly between the two groups (P > 0.05, Table 2).
After 1 year of follow-up, the rate of MACCEs was
lower in the fondaparinux group than in the enoxaparin
group (10.9 % vs 12.6 %, P = 0.433), although the differ-
ence was not marked. The incidence of cardiac mortal-
ity, nonfatal MI, TVR, and stroke did not differ
significantly between the fondaparinux and enoxaparin
groups (P > 0.05). The rate of all bleeding events was
significantly lower in the fondaparinux group than in the
enoxaparin group at 30 days (0.9 % vs 2.8 %, P = 0.040)
and at 1 year (2.4 % vs 5.4 %, P = 0.018). Although the in-
cidence of major bleeding events was lower in the fonda-
parinux group than in the enoxaparin group at 30 days
(0.23 % vs 0.88 %, P = 0.429) and at 1 year (0.23 % vs
1.1 %, P = 0.253), the difference was not significant
(Table 3).
Figure 2 shows the efficacy and safety of fondaparinux
and enoxaparin in patients undergoing PCI. After adjust-
ing for age, sex, and administration of antiplatelet drugs,
the incidence rate of all bleeding events was significantly
Fig. 1 Trial profile. Abbreviations: PCI, percutaneous coronary intervention; CABG, Coronary Artery Bypass Grafting; GPI, glycoprotein IIb/IIIa inhibitor
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Table 1 Baseline characteristics of the fondaparinux and enoxaparin groups
Characteristics Fondaparinux (n = 430) Enoxaparin (n = 463) P
Age (year) 57.29 ± 9.39 58.16 ± 9.58 0.170
Male [n(%)] 328 (76.3) 363 (78.2) 0.486
Weight (kg) 72.04 ± 12.08 72.64 ± 13.05 0.487
Hypertension [n(%)] 245 (57.2) 276 (59.5) 0.448
Diabetes [n(%)] 98 (22.8) 94 (20.3) 0.357
Stroke [n(%)] 14 (3.3) 11 (2.4) 0.423
Prior myocardial infarction [n(%)] 50 (11.6) 74 (15.9) 0.060
Current smoker [n(%)] 224 (52.1) 246 (53.0) 0.782
ACS [n(%)]
Unstable angina 216 (50.2) 296 (68.3) 0.658
Non-ST-elevation ACS 52 (12.1) 49 (10.6) 0.477
ST-elevation MI 162(37.7) 119 (25.6) <0.001
Target vessel position [n(%)]
Left Main 53 (12.3) 66 (14.2) 0.397
Left Anterior Descending 278 (64.7) 295 (63.6) 0.771
Left Circumflex 36 (8.4) 39 (8.4) 0.978
Right Coronary Artery 46 (10.9) 45 (9.7) 0.629
PCI
Average stent diameter (mm) 3.03 ± 0.40 3.06 ± 0.40 0.181
Average length of stents (mm) 27.17 ± 5.96 27.58 ± 5.89 0.293
Average number of stents 1.85 ± 0.96 1.89 ± 1.02 0.627
Transradial artery invasive [n(%)] 378 (87.9) 408 (87.9) 0.991
Tirofiban (d) 1.84 ± 0.66 1.90 ± 0.62 0.495
Fondaparinux/enoxaparin (d) 4.75 ± 1.81 4.57 ± 1.75 0.168
Laboratory examination
APTT (s) 33.39 ± 5.86 32.97 ± 5.57 0.271
Prothrombin time (s) 12.97 ± 1.38 12.90 ± 1.07 0.381
HDL-C (mmol/L) 1.19 ± 0.44 1.18 ± 0.58 0.639
Creatinine (mmol/L) 87.50 ± 18.71 91.02 ± 15.02 0.116
PLT (×109/L) 212.29 ± 56.09 212.50 ± 51.13 0.954
ACS Acute coronary syndrome, MI Myocardial infarction, PCI Percutaneous coronary intervention, APTT Activated partial thromboplastin time, HDL-C High-density
lipoprotein cholesterol. All values are expressed as means ± SD. P < 0.05 was considered to indicate statistical significance
Table 2 Application of drugs during follow-up
Medicine Fondaparinux (n = 422) Enoxaparin (n = 453) P
Aspirin [n(%)] 419(99.3) 452(99.8) 0.567
Clopidogrel [n(%)] 338(80.1) 341(75.3) 0.088
ACE inhibitor or ARB [n(%)] 353(83.6) 379(83.7) 0.995
Calcium-channel blocker [n(%)] 69(16.4) 72(15.9) 0.854
Beta-blocker [n(%)] 360(85.3) 398(87.9) 0.268
Statin [n(%)] 397(94.0) 425(93.8) 0.874
P < 0.05 was considered to indicate statistical significance
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lower in the fondaparinux group than the enoxaparin
group at 1 year of follow-up, according to the concomi-
tant use of GPI (P = 0.023). After adjusting for age, sex,
weight and other cardiovascular disease risk factors,
fondaparinux did not increase the risk of MACCEs com-
pared with enoxaparin (P = 0.411, Fig. 3).
We also evaluated the incremental risk factors in these
patients at high risk for MACCEs and found that history
of diabetes was an independent risk factor for the inci-
dence of MACCEs. Male sex, age, prior PCI, and other
factors were not significantly associated with MACCE
incidence (Table 4).
Discussion
Currently, multiple agents are used in clinical work [17].
The application of thrombin inhibitors and invasive treat-
ments can substantially reduce the occurrence of ischemic
events but can also increase the incidence of bleeding in
patients with ACS. Among these antiplatelet agents, GPIs
exhibit a significant benefit regarding the occurrence of
MI events and mortality in patients with ACS; however,
GPIs also lead to a 60 % increase in bleeding (OR = 1.62,
95 % CI: 1.36–1.94) [18]. Several studies have found that
GPIs can increase the occurrence of MI events, stroke and
death in patients with bleeding events [12, 19]. The mech-
anisms behind the increased mortality or morbidity asso-
ciated with bleeding are unclear, but may be associated
with fatal bleeding, hemorrhagic shock, hypoxia (possibly
of particular relevance in STEMI patients), cessation of
therapy (such as β-blockers and ACE inhibitors), systemic
Table 3 Clinical outcomes at one year in patients undergoing
PCI [n(%)]
Variables Fondaparinux (n = 422) Enoxaparin (n = 453) P
MACCEa 46 (10.9) 57 (12.6) 0.433
Death or MI 18 (4.3) 24 (5.3) 0.475
Death 2 (0.5) 7 (1.5) 0.116
MI 16 (3.8) 17 (3.8) 0.976
TVR 23 (5.5) 28 (6.2) 0.645
Stroke 7 (1.7) 9 (2.0) 0.717
30 day
Major bleeding 1 (0.23) 4 (0.88) 0.429
All bleedingb 4 (0.95) 13 (2.9) 0.040
1 year
Major bleeding 1 (0.23) 5 (1.1) 0.253
All bleedingb 10 (2.4) 25 (5.5) 0.018
MI Myocardial infarction, TVR Target vessel revascularization. aMACCE:
including death from cardiovascular causes, non-fatal myocardial infarction
and target vessel revascularization. bAll bleeding was defined using the TIMI
definition. P < 0.05 was considered to indicate statistical significance
Fig. 2 Efficacy of fondaparinux and enoxaparin in patients undergoing
percutaneous coronary intervention. MACCE, including death from
cardiovascular causes, non-fatal myocardial infarction and target
vessel revascularization. P < 0.05 was considered to indicate
statistical significance
Fig. 3 Safety of fondaparinux and enoxaparin in patients undergoing
percutaneous coronary intervention. P< 0.05 was considered to indicate
statistical significance
Table 4 Odds ratios for the morbidity of MACCE
Variable OR 95 % CI P
Male 0.784 0.454–1.356 0.384
Age 1.017 0.994–1.041 0.155
ACS 1.024 0.806–1.300 0.848
Diabetes 2.028 1.298–3.169 0.002
Creatinine 0.991 0.977–1.005 0.206
Prior PCI 1.424 0.821–2.471 0.208
Prior myocardial infarction 1.126 00619–2.047 0.697
NYHA functional classification 1.035 0.663–1.614 0.881
ACS Acute coronary syndrome. P < 0.05 was considered to indicate
statistical significance
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inflammation, adverse effects of transfusion and visceral
dysfunction [20–23]. Because of the serious long-term
consequences of major bleeding, treatment strategies that
can reduce the risk of bleeding while maintaining the ben-
efits of decreasing ischemic events are required. In our
study, we found that fondaparinux significantly decreased
the incidence of bleeding events in patients undergoing
PCI with GPI, representing an alternative to enoxaparin
that preserves efficacy while improving safety [13].
In the OASIS-5 trial, fondaparinux reduced major
bleeding by 48 % at 9 days in patients undergoing PCI
with non-ST-segment elevation ACS, which was associ-
ated with a 17 % mortality reduction at 30 days [13].
However, the rate of catheter-related thrombosis was
higher in those treated with fondaparinux than with
enoxaparin (0.9 % vs 0.4 %, respectively), which limited
the widespread adoption of fondaparinux for patients
with ACS. In the FUTURA/OASIS-8 trial, we found a
higher rate of guiding catheter-related thrombosis in pa-
tients who had undergone PCI that was performed with-
out UFH; however, this higher rate was largely avoided
when UFH was used before the procedure [24].
In the present study, we found that the incidence of
MACCEs and cardiac mortality was lower in the fonda-
parinux group than in the enoxaparin group. Further-
more, the incidence of all bleeding events was significantly
lower in the fondaparinux group than in the enoxaparin
group. We also evaluated incremental risk factors in pa-
tients at a high risk of MACCEs and found that diabetes
was an independent risk factor of MACCEs in patients
with ACS.
In the OASIS-6 trial, the incidence of major bleeding
events was not increased by the application of fondapari-
nux; furthermore, cardiac tamponade was clearly reduced,
and a trend towards fewer fatal bleeding events was
observed [14]. The trend toward lower rates of fatal and
life-threatening bleeding was consistent with the markedly
lower rates of bleeding in the fondaparinux group com-
pared with the enoxaparin group found in the OASIS-5
trial. This finding suggests that fondaparinux might de-
crease the risk of major bleeding at the doses used. In our
present trial, we found that fondaparinux significantly
reduced the rate of bleeding and resulted in a lower inci-
dence of MACCEs compared with enoxaparin. One pa-
tient in the enoxaparin group exhibited gastrointestinal
bleeding (major bleeding as defined by TIMI) at 1 day
after PCI; antithrombotic therapy and aspirin were discon-
tinued, and the dose of clopidogrel was changed to
150 mg/day. However, after 4 days, the patient died from
cardiogenic shock and organ failure. We consider that, in
addition to cardiogenic shock and liver and kidney dys-
function in patients with AMI, the cessation of antithrom-
botic therapy and decreased oxygen delivery have adverse
effects on prognosis. Further study is needed to elucidate
the association of bleeding and ischemic events, and the
specific mechanisms involved.
Compared with LMWH, fondaparinux was found to
specifically inhibit and reduce the production of factor
Xa but did not completely prevent the formation of
thrombin. This drug also prevented excessive anticoagu-
lation, a finding that partly explains why fondaparinux
has a stable anticoagulant effect and does not increase
bleeding in patients with ACS. Particularly in patients
with advanced age, diabetes mellitus or renal insuffi-
ciency, fondaparinux has a half-life of 15 h, obviating the
need for laboratory monitoring; thus, fondaparinux can
be recommended.
Our study had the following limitations. First, the follow-
up was short and the sample was small; therefore, longer
follow-up and larger sample size are needed. Second, the
study was retrospective, which inevitably resulted in re-
call bias.
Conclusions
In summary, in patients with ACS treated with GPI tiro-
fiban undergoing PCI, the efficacy of fondaparinux is not
inferior to that of enoxaparin. However, fondaparinux
could decrease the incidence of bleeding after PCI; there-
fore, fondaparinux treatment for ACS is safe and can be
recommended.
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